• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局限性食管鳞状细胞癌的延长化疗

Prolonged chemotherapy for localised squamous carcinoma of the oesophagus.

作者信息

Ajani J A, Ryan B, Rich T A, McMurtrey M, Roth J A, DeCaro L, Levin B, Mountain C

机构信息

UT M.D. Anderson Cancer Center, Houston 77030-4096.

出版信息

Eur J Cancer. 1992;28A(4-5):880-4. doi: 10.1016/0959-8049(92)90140-w.

DOI:10.1016/0959-8049(92)90140-w
PMID:1524915
Abstract

We evaluated the feasibility of six courses of chemotherapy in 34 consecutive patients with localised squamous cell carcinoma of the oesophagus. All 32 evaluable patients first received at least two courses of chemotherapy. There were 18 patients with resectable carcinomas who underwent surgery and 14 patients with unresectable carcinomas who received definitive chemoradiotherapy. After two courses of 5-fluorouracil and cisplatin 21 (66%) of 32 patients had either a complete or major response. A median of five courses (range, 1-6 courses) was administered. 17 out of 18 (94%) patients with resectable carcinoma had a 'curative' resection (negative proximal, distal, and radial margins by histopathology in an en-block resection specimen) and 2 patients had a complete pathological response. The median survival duration of all patients was 28 months (range, 2-46+ months). The median survival duration of 14 patients with unresectable carcinoma was 23 months (range, 8-36+ months), and the median survival duration of 18 patients with resectable carcinoma has not been reached at a median follow-up of 24+ months (range, 10+ to 46+ months). No deaths occurred because of chemotherapy or chemoradiation therapy. Our data suggest that prolonged chemotherapy is feasible in patients with locoregional squamous carcinoma of the oesophagus. An ongoing controlled trial will determine the contribution of chemotherapy to patients' survival.

摘要

我们评估了连续34例局限性食管鳞状细胞癌患者接受六个疗程化疗的可行性。所有32例可评估患者首先接受了至少两个疗程的化疗。其中18例可切除癌患者接受了手术,14例不可切除癌患者接受了根治性放化疗。在接受两个疗程的5-氟尿嘧啶和顺铂治疗后,32例患者中有21例(66%)出现完全缓解或主要缓解。化疗疗程中位数为五个疗程(范围1 - 6个疗程)。18例可切除癌患者中有17例(94%)进行了“根治性”切除(整块切除标本的组织病理学检查显示近端、远端和径向切缘阴性),2例患者出现完全病理缓解。所有患者的中位生存时间为28个月(范围2 - 46 +个月)。14例不可切除癌患者的中位生存时间为23个月(范围8 - 36 +个月),18例可切除癌患者在中位随访24 +个月(范围10 +至46 +个月)时,中位生存时间尚未达到。未发生因化疗或放化疗导致的死亡。我们的数据表明,延长化疗对局部区域食管鳞状癌患者是可行的。一项正在进行的对照试验将确定化疗对患者生存的贡献。

相似文献

1
Prolonged chemotherapy for localised squamous carcinoma of the oesophagus.局限性食管鳞状细胞癌的延长化疗
Eur J Cancer. 1992;28A(4-5):880-4. doi: 10.1016/0959-8049(92)90140-w.
2
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.对于潜在可切除的食管癌或食管胃交界癌患者,采用先诱导化疗、然后同步放化疗、最后手术的三步策略。
Cancer. 2001 Jul 15;92(2):279-86. doi: 10.1002/1097-0142(20010715)92:2<279::aid-cncr1320>3.0.co;2-2.
3
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.术前顺铂、持续输注5-氟尿嘧啶和44Gy放疗用于食管癌的成熟生存结果。
Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):328-34. doi: 10.1016/s0360-3016(02)04598-4.
4
Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction.
Eur J Cancer. 1995;31A(5):665-70. doi: 10.1016/0959-8049(94)00318-y.
5
Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction.局部晚期下食管癌和胃食管交界癌的术前序贯化疗和放化疗
Eur J Cancer. 1998 Apr;34(5):668-73. doi: 10.1016/s0959-8049(97)10109-5.
6
First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up.一线化疗可提高局部晚期(T4,任何N,M0)胸段食管鳞状细胞癌的切除率和长期生存率:163例连续患者5年随访的最终报告
Ann Surg. 1997 Dec;226(6):714-23; discussion 723-4. doi: 10.1097/00000658-199712000-00008.
7
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.对食管或胃食管交界部局部区域癌患者,术前进行伊立替康和顺铂诱导化疗,随后进行放化疗。
Cancer. 2004 Jun 1;100(11):2347-54. doi: 10.1002/cncr.20284.
8
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
J Clin Oncol. 1990 Jul;8(7):1231-8. doi: 10.1200/JCO.1990.8.7.1231.
9
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.食管T4和/或M1淋巴结鳞状细胞癌的根治性放化疗。
J Clin Oncol. 1999 Sep;17(9):2915-21. doi: 10.1200/JCO.1999.17.9.2915.
10
Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.顺铂和依托泊苷联合进行有效放化疗用于治疗局部无法手术及转移性食管癌患者。
Cancer. 1996 Oct 15;78(8):1646-50.

引用本文的文献

1
Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer.多西他赛、顺铂和5-氟尿嘧啶辅助化疗用于II/III期N1、2期食管癌三野淋巴结清扫术后
Mol Clin Oncol. 2014 Sep;2(5):719-724. doi: 10.3892/mco.2014.320. Epub 2014 Jun 19.
2
Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus.Rad51 表达是预测食管鳞癌新辅助放化疗疗效的有用指标。
Ann Surg Oncol. 2014 Feb;21(2):597-604. doi: 10.1245/s10434-013-3220-2. Epub 2013 Sep 25.
3
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.
多药耐药相关蛋白 2(MRP2)在食管鳞癌化疗耐药和临床结局中的作用。
Br J Cancer. 2011 Feb 15;104(4):707-13. doi: 10.1038/sj.bjc.6606071. Epub 2011 Jan 4.
4
Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.食管胃结合部腺癌:发病率、特征和治疗策略。
Gastric Cancer. 2010 Jun;13(2):63-73. doi: 10.1007/s10120-010-0555-2. Epub 2010 Jul 3.
5
Esophageal cancer chemotherapy: recent advances.食管癌化疗:最新进展
Gastrointest Cancer Res. 2008 Mar;2(2):85-92.
6
Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse.一例食管癌伴乳腺及脑转移经化疗与手术联合治疗后的成功结果。
World J Gastroenterol. 2006 Sep 14;12(34):5565-8. doi: 10.3748/wjg.v12.i34.5565.
7
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.食管鳞状细胞癌的新辅助治疗:通过正电子发射断层扫描进行疗效评估
Ann Surg. 2001 Mar;233(3):300-9. doi: 10.1097/00000658-200103000-00002.
8
Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect.
Surg Today. 1999;29(8):689-94. doi: 10.1007/BF02482310.
9
Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus.5-氟尿嘧啶与低剂量顺铂用于食管癌鳞状细胞癌患者的II期试验。
Surg Today. 1999;29(2):97-101. doi: 10.1007/BF02482231.
10
Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.顺铂和紫杉醇联合化疗用于局部晚期、复发或转移性食管癌患者。
Br J Cancer. 1998 Aug;78(4):511-4. doi: 10.1038/bjc.1998.524.